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Abstract. L-selectin expressed by granulocytes, lym- 
phocytes, and monocytes i responsible for initial leu- 
kocyte attachment to inflamed endothelium and high 
endothelial venules of peripheral lymph nodes. After 
leukocyte activation in vitro, L-selectin is rapidly shed 
from the cell surface. In this study, shed L-selectin 
(sL-selectin) from both lymphocytes and neutrophils 
was demonstrated to be present in high levels in hu- 
man plasma by Western blot analysis and using a quan- 
titative ELISA. In serum from normal human blood 
donors, a mean sL-selectin level of 1.6 ___ 0.8 #g/ml 
(n = 63) was found by ELISA. In addition, semi- 
purified sL-selectin from plasma inhibited L-selectin- 
specific attachment of lymphocytes to cytokine- 
activated endothelium in a dose-dependent manner. 
L-selectin-dependent leukocyte attachment was com- 
pletely inhibited at sL-selectin concentrations of 8-15 
/zg/ml, while physiological concentrations of sL- 
selectin caused a small but consistent inhibition of 
lymphocyte attachment, sL-selectin in plasma also in- 
hibited anti-L-selectin mAb (2-5 #g/ml) binding to 
the surface of leukocytes. Interestingly, one epitope 
present within the EGF-like domain of L-selectin was 
lost in sL-selectin, suggesting a conformational change 
in the structure of the receptor after shedding. The 
presence of serum sL-selectin with functional activity 
indicates a potential role for sL-selectin in the regula- 
tion of leukocyte attachment to endothelium. 
T 
HE ability of leukocytes to leave the circulation and 
to migrate into tissues is a critical feature of the im- 
mune response. Several adhesion molecules are in- 
volved in the process of adhesion and transmigration of 
leukocytes through vascular endothelium at sites of inflam- 
mation (45). One molecule responsible for the initial attach- 
ment of leukocytes to endothelium is L-selectin (Leukocyte 
Adhesion Molecule-1 [LAM-1] t MEL-14) (24, 30, 43, 44). 
L-selectin is a member of the selectin family of adhesion 
molecules (3, 11, 27, 36, 37, 49) that includes E-selectin 
(Endothelial-Leukocyte Adhesion Molecule-1 [ELAM-1]) (1, 
2, 31, 32) and CD62 (P-selectin, PADGEM, GMP-140) (13, 
18, 25, 26). The selectins are derived from evolutionarily re- 
lated genes (7, 9, 18, 33, 52), and are characterized by a 
NH2-terminal, Ca-dependent lectin domain, an epider- 
mal growth factor (EGF)-like domain followed by multi- 
ple short consensus repeat (SCR) domains, a transmem- 
brane region, and a cytoplasmic tail. 
L-selectin is expressed on the surface of most leukocytes, 
including lymphocytes, neutrophils, monocytes, eosinophils, 
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1. Abbreviations used in this paper: ELAM-1, endothelial-leukocyte adhe- 
sion molecule; HEV, high endothelial venule of peripheral lymph nodes; 
LAM-I, leukocyte adhesion molecule-l; SCR, short consensus repeat; 
TNF, tumor necrosis factor; sL-selectin, shed L-selectin. 
hematopoietic progenitor cells, and immature thymocytes 
(14, 51). L-selectin is a highly glycosylated protein of 95-105 
kD on neutrophils and 74 kD on lymphocytes (14, 50). 
Human and mouse L-selectin mediate the binding of lym- 
phocytes to high endothelial venules (HEV) of peripheral 
lymph nodes through interactions with a constitutively ex- 
pressed ligand (16, 23, 40, 46, 51), and are also involved in 
lymphocyte, neutrophil, and monocyte attachment toendo- 
thelium at sites of inflammation (15, 20, 29, 39, 43, 44, 54). 
In vitro, endothelial cell surface xpression of the L-selectin 
ligand(s) is induced only after exposure of the endothelial 
cells to inflammatory cytoldnes, and the endothelial ligand 
shares many functional features with the L-selectin ligand(s) 
expressed by HEV (39, 43). Sulfated carbohydrates and 
mAbs which bind to the lectin domain of L-selectin, inhibit 
L-selectin-specific adhesion (16, 21, 43, 47, 56, 57). Thus, 
the lectin domain of L-selectin seems to mediate ligand bind- 
ing, while the EGF-like and SCR domains may somehow 
regulate the affinity of this interaction (21, 38, 41, 42, 55). 
A unique feature of L-selectin is that it is shed from the 
cell surface after cellular activation in vitro (14, 19, 22, 23, 
40). It has been proposed, at least in the mouse model, that 
shedding of MEL-14 from leukocytes might be necessary to 
enable leukocytes to transmigrate hrough endothelium into 
sites of inflammation in vivo (20, 22). This would provide 
a rapid means for the regulation of leukocyte adhesion and 
deadhesion to endothelium. Although the subsequent fate 
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and possible function of the shed L-selectin (sL-selectin) 
molecule is not known, elegant studies by Woodruff and 
colleagues have previously demonstrated the presence of a 
soluble factor in rat thoracic duct lymph capable of inhibit- 
ing lymphocyte binding to HEV (4). Furthermore, they 
demonstrated that this factor was antigenically related to a 
structure(s) present on lymphocytes and speculated that this 
cell-surface molecule might play a role in adherence of lym- 
phocytes to HEV of lymph nodes (4, 5, 6). 
A number of surface molecules present on cells of various 
lineages are now known to be shed and thereby released into 
the extracellular milieu (48). These include the receptors for 
interleukin-1, intedeukin-2 (CD25), transferrin (CD71), in- 
sulin, growth hormone, tumor necrosis factor (34), colony- 
stimulation factor-1 (10), and nerve growth factor (8), as well 
as CD8 and CD14. These proteins are quite diverse in struc- 
ture and amino acid sequence and have no unifying func- 
tional characteristics that are currently appreciated. In most 
cases, proteases cleave the receptor near the membrane, 
releasing a nearly intact extracellular domain with ligand- 
binding activity (8, 10, 22, 40). Thus, receptor function may 
not only be regulated by proteolytic leavage of the receptor 
from the cell surface, but also by the presence of shed recep- 
tor in the extracellular environment. The present study 
shows that sL-selectin from neutrophils and lymphocytes i  
found in plasma at high levels and that it may retain func- 
tional activity. Since sL-selectin inhibited L-selectin-medi- 
ated adhesion in vitro, it may modulate leukocyte binding to 
endothelium in vivo. 
Materials and Methods 
Antibodies 
L-selectin directed mAbs were the anti-LAM1-3, -4, -6, -7, -8, -10, -11, and 
-12 mAbs directed against epitopes within the lectin domain, anti-LAMl-1, 
-5 and -15 reactive with epitopes within the EGF-like domain and anti- 
LAMl-14 which reacts with the SCR regions of L-selectin, all of the IgGl 
isotype (42). The anti-L-selectin mAbs were purified by salt fractionation 
followed by anion exchange chromatography, with the mAb concentration 
determined by light absorption. The anti-LAM1-3 mAb was bound to 
CNBr-activated Sepharose 4B (Pharmacia LKB Biotechnology Inc., Pis- 
caraway, N J) at 2.5 nag of mAb bound per 1 ml of beads (anti-LAM- 
Sepbarose) using the methods of the manufacturer. 
Isolation of Blood Mononuclear Cells 
Heparinized blood was obtained according to protocols approved by the Hu- 
man Protection Committee of Dana-Farber Cancer Institute, Boston, MA. 
Mononuclear cells were isolated by Ficoll Hypaque density gradient cen- 
trifugation. Cells were immediately resuspended in RPMI 1640 (Gibco- 
BRL, Gaithersburg, MD) containing 10% FCS and kept at 4~ until use. 
In most instances, these cells will be referred to as lymphocytes ince 
85-95 % of the cell population was lymphocytes as determined bymorphol- 
ogy (Wright's tain) and flow cytometry analysis. Neutrophils were purified 
by centrifugation  a cushion of Mono-Poly Resolving Medium (Flow 
Laboratories, Inc., McLean, VA) followed by lysis of the red cells with ice- 
cold hypotonic 0.2% (wt/vol) NaCI solution. Neutrophils were finally 
resuspended in HBSS containing 5 % FCS (Sigma Chemical Co., St. Louis, 
MO). When sL-selectin was obtained for Western blot analysis, the 
mononuclear cells were first incubated in plastic dishes for 30 min in 
RPMI/10% FCS at 37~ to remove adherent monocytes. Nonadherent cells 
retained surface L-selectin and were predominantly lymphocytes (•99 %). 
Cell Cultures 
Lymphocytes were cultured in 24-well plates (Costar Corp., Cambridge, 
MA) at 106/ml in RPMI 1640 medium containing 10% FCS, 2% L-glu- 
tamine, penicillin, and streptomycin. The cells were cultured with PMA 
(100 ng/ml) for 60 min before the culture medium was harvested and tested 
for sL-selectin by ELISA. Neutrophils were incubated in polypropylene 
tubes at 8 • 106 cells/ml for 60 rain at 37~ either in HBSS/5% FCS 
medium alone or containing granulocyte/monocyte-colony stimulating fac- 
tor (25 ng/ml; a gift from Drs. Steven Clark and Gordon Wong, Genetics 
Institute, Cambridge, MA), monocyte-colony stimulating factor (100 
ng/ml; Genetics Institute), tumor necrosis factor-c~ (TNF-c~; 100 U/ml; 
Genzyme Corp., Cambridge, MA), lipopolysaccharide (I /zg/ml; Esche- 
richia coli 011:IM; Sigma Chemical Co.), formyl-methionyl-leucyl- 
phenylalanine (10 -s M; Sigma Chemical Co.), interferon- 7 (1,000 U/ml; 
Genzyme Corp.), or interleukin-1/3 (10 U/ml; Genzyme Corp.). After cul- 
ture, the supernatant fluid was tested for the presence of sL-selectin by 
ELISA. The human erythroleukemia cell line, K562, was transfected with 
the pLAM-1 eDNA as previously described (51) and will be called IO62- 
LAM throughout. These cells were cultured in RPMI 1640/10% FCS and 
were kept at cell numbers between 0.2 and 1 • 106 ceUs/ml. All cells were 
incubated at 37~ in 5% CO2 with 100% humidity. 
Indirect Immunofluorescence Analysis 
Indirect immunofluorescence analysis was carried out after washing the 
cells three times. Cells (1 x 106 cells) were resuspended in 100/zl of me- 
dia containing various concentrations of the indicated mAb, and incubated 
for 60 rain at 4"C. After washing, the cells were treated with FITC- 
conjugated goat anti-mouse Igantibodies (Southern Biotechnology Associ- 
ates, Birmingham, AL) for 20 min at 4~ The cells were washed, and fixed 
(1% paraformaldehyde in PBS), and single color fluorescence was deter- 
mined on a flow cytometer (ELITEr'; Coulter Immunology, Hialeah, FL). 
10,000 cells were analyzed for each sample and the relative mean fluores- 
cence intensity of L-selectin + cells was determined on a linear scale. 
In some experiments, cells were stained in the presence of human 
plasma, sL-selectin was precleared from an aliquot of the same plasma by 
immunoprecipitation with anti-LAM-Sepharose (I ml of beads per 4 ml of 
plasma). The efficiency of the immunoprecipitations wa tested by ELISA 
(<20 ng/ml). Lymphocytes (I x 106) were resuspended ither in 100/zl of 
plasma or precleared plasma containing various concentrations of the 
purified mAb (added 1:100) as indicated. The cells were washed twice, 
stained, and analyzed as above. 
sL-selectin Purification 
sL-selectin was semipurified from plasma obtained from heparinized hu- 
man blood. Plasma was salt-fractionated with Na2SO4 (18% wt/vol) before 
the sL-selectin containing supernatant fraction was dialyzed against 0.02 M 
Tris buffer, pH 8.0, 0.5 M NaCI. The sL-selectin preparation was further 
purified by affinity column chromatography using anfi-LAM-Sepharose. 
sL-selectin was eluted from the column with 0.1 M Na a~etate buffer, pH 
3.5, 0.15 M NaC1, and the low pH of the eluate was immediately raised by 
the addition of 2.0 M Tris buffer, pH 9.0. The pooled fractions of the eluate 
peak were concentrated and transferred into PBS by ultrafiltration. The con- 
centration of sL-selectin was determined by ELISA and subsequently ad- 
justed to ,~15 #g/ml in PBS. At this sL-selectin concentration, the total pro- 
tein concentration f the samples varied between 130 and 220/~g/ml, and 
sL-selectin represented "~6-10 % of total protein. In general, this procedure 
gave a 2,200-3,700-fold enrichment for sL-selectin. For use in lymphocyte- 
endothelial dhesion assays, semipurified sL-selectin was transferred into 
RPMI 1640/10% FCS by further ultraliltration. 
Western Blot Analysis 
sL-selectin was semipurified from plasma s described above and further 
purified by immunoprecipitation using anti-LAM-Sepharose with repeated 
washing of the beads in alternating high salt (0.5 M NaCI, 0.2% Na- 
deoxycholate) and low salt (0.125 M NaCI, 0.05 % Na-deoxycholate) RIPA 
buffer (100 mM Tris, pH 8.0, 1% [vol/vol] Triton X-100, 10 mM EDTA, 
10 mM EGTA, I0 mM NaF, 1 mg/ml BSA). Proteins were elu~,xl from the 
beads with 0.1 M acetate buffer, pH 3.5, 0.15 M NaC1. Supernatant fluid 
from PMA-stimulated cells was also analyzed. Cells (1 x 107/ml), includ- 
ing neutrophils (10 ng/ml PMA in RPMI 1640 for 10 rain at 37~ lympho- 
cytes (10 ng/ml PMA in RPMI 1640 for 25 rain at 37~ and K562-LAM 
transfectants (100 ng/ml PMA in PBS for 120 rain at 37~ were induced 
to shed essentially all detectable cell surface L-selectin, before being 
pelleted by centrifugation (4~ 400 g, 10 min). The supernatant fluid was 
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saved and concentrated 10-fold by ultrafiltration (Amieon Corp., Danvers, 
MA). Protein samples (100 ~1) were applied to a 7.5 % SDS-polyacrylamide 
gel, electrophoresed, and blotted onto nitrocellulose. Western blot analysis 
was performed using the anti-LAMl-14 mAb (ascites, 1:2,000) as the 
antigen-detecting a tibody. The blot was developed using alkaline phospha- 
tase conjugated goat anti-mouse IgG1 antibody (Southern Biotechnology 
Associates) and NBT/BCIP as substrate (Promega Corp., Madison, WI). 
In preliminary experiments, he anti-LAMl-14 mAb was the most sensitive 
of the 12 anti-L-selectin mAbs tested, of which anti-LAM1-3, -4, -8, -10, 
and -15 mAb were also found to give positive staining. 
Endothelial-Leukocyte Attachment Assay 
Lymphocyte adhesion to cytoldne-activated endothelium under nonstatic 
conditions was determined in a test system adapted from the Stamper/ 
Woodruff assay for frozen tissue sections (46) exactly as described (43). 
Briefly, human umbilical vein endothelial cells (HUVEC) were isolated 
from cord veins, and grown in M199 medium supplemented with 10% FCS, 
endothelial cell growth factor (50 t~g/ral, Biomedical Technologies, Inc., 
Stoughton, MA) and porcine intestinal beparin (50 mg/ml; Sigma Chemical 
Co.) as described (43). Endothelial cells were grown to confluence on gela- 
tin (0.1%)-coated glass slides and stimulated with TNF-a (100 U/ml) at 
37~ for the times indicated. The monolayers were carefully washed and 
incubated at4~ for 15 rain with 75/zl of RPMI/10% FCS alone or contain- 
ing semipurified sL-selectin. As a control, in some instances media contain- 
ing semipurified sL-selectin were precleared by immunoprecipitation with 
anti-LAM-Sepharose. Without further washing, 5 • 106 lymphoeytes in 
75 t21 of the respective media were added. After 20 rain of incubation at 
4~ with rotation at 64 rpm, the slides were fixed overnight in glutaralde- 
hyde (1% [vol/vol] in PBS; Polysciences, Warrington, PA), and stained with 
hematoxylin. The number of adherent leukooytes was determined bycount- 
ing six microscopic fields (0.09 mm2/field) and the results were expressed 
as means + SD. 
Production of the L-selectin and IgG Chimera cDNA 
and Protein 
Generation ofthe L-selectin and IgG chimeric DNA will be described in 
detail elsewhere (44a). Basically, the 1400-bp BanlI fragment from a eDNA 
encoding the CH1 through CH3 domains of the human IgGl constant re- 
gion was inserted at a BanlI site introduced into pLAM-1 cDNA (49) 
(amino acid number 370 in the membrane proximal region of the mature 
protein) by oligonucleotide directed mutngenesis. The recombinant DNA 
was sequenced and the conservation f L-selectin and IgG~ restriction sites 
in the pLAM-IgG DNA was contirmed by restriction mapping. The LAM- 
IgG DNA was subeloned into the AprM8 expression vector (provided by 
Dr. Lloyd Klickstein, Center for Blood Research, Boston, MA) and used 
to transiently transfect COS cells by the DEAE dextran method. The trans- 
fected COS cells were cultured in AIM-V serum-free media (Gibeo-BRL) 
and the supernatant fluid containing the chimeric LAM-IgG fusion protein 
was harvested after 3 d. 
sL-selectin ELISA 
The ELISA used to quantitate sL-selectin levels in biological f uids will be 
described in detail elsewhere (44a). Briefly, wells of microtiter plates (96 
welt, flat bottom, E.I.A./R.I.A. plate, Costar, Cambridge, MA) were 
coated with anti-L-selectin r Ab as indicated. After washing with TBS, the 
wells were blocked with 2% BSA and 1% gelatin in TBS. The wells were 
washed, and the test samples were added to triplicate wells. Each assay in- 
cluded the titration of a previously quantified plasma sample that was used 
to generate a standard curve. After washing, the plates were incubated with 
biotinylated anti-LAM1-3 mAb (1 /~g/ml) for 60 rain at 20~ The wells 
were washed, and avidin-HRP (0.1/zg/ml, Pierce Chemical Co., Rockford, 
IL) was added for 30 rain at 20~ Again, the plates were washed and finally 
developed using o-phenylenediamine (0.125% wt/vol, Sigma Chemical 
Co.) as a substrate in0.1 M citrate buffer, pH 4.5, in the presence of H202. 
The OD of the reaction mixture was quantitated using an ELISA-reader 
(Vmax kinetic microplate reader; Molecular Devices, Menlo Park, CA). 
Results were obtained when the OD for the well containing the highest con- 
centration ofstandard plasma was ,00.8 at 495 nm. The relative concentra- 
lion of sL-selectin in individual samples was calculated by comparing the 
mean OD obtained for triplicate wells with a semilog standard curve of 
titrated plasma using linear regression analysis (r ~ 0.97). 
The amount of sL-selectin present in the standard plasma was quantitated 
in two ways. First, K562-LAM-1 cells ('011 liters of cultured ceils, "01.1 
x 10 l~ cells) were resuspended in PBS (1 x 107 cells/ml) and were stimu- 
lated with PMA (100 ng/ml) for 2 h at 37~ The supernatant fluid was 
collected, concentrated byultrafiltration, and affinity purified by column 
chromatography using anti-LAM-Sepharose as described above. The semi- 
purified sample was electrophoresed on a 10% SDS-polyacrylamide g l 
that was subsequently stained by Coomassie blue to reveal a prominent 71- 
kD band and additional bands of eul80, 57, 47, and 22 kD. The gel was 
scanned using a Hewlett Packard Desk Scanner and the density of the 7 l-kD 
band was quantitated against a standard curve generated with BSA using 
the Enlmnce TM program (Microsystems, Des Moines, IA) on an Apple 
Macintosh Ilcx computer. The concentration f sL-selectin i  the standard 
plasma was calculated to be "01.3 t~g/ml by comparing the signal from semi- 
purified sL-selectin to the L-selectin-ELISA titration curve of standard 
plasma with linear egression analysis. The detection limit of the L-selectin- 
ELISA was determined to be ;~5 ng/ml. In a second set of experiments, COS 
cells were grown in serum-free medium after transient transfection with the 
LAM-IgG chimera eDNA. Supernatant fluid was collected from the cells 
and run over a Protein A-Sepharose (Pharmacia LKB Biotechnology) 
affinity chromatography column and the fusion protein was duted from the 
column by high salt-tow pH buffer. The purified fusion protein was quanti- 
tated after SDS-PAGE analysis by comparison of the stained protein band 
with a standard curve of BSA. From this analysis, it appeared that OD 
values for standard plasma would be equivalent to"01.9 t~g/ml of LAM-IgG 
fusion protein. Since the dimeric nature of the fusion protein might double 
the intensity of staining in our sandwich ELISA, the amount of sL-setectin 
in the standard plasma may be half the value of ,ol.9/~g/mt. 
Statistics 
Statistical analysis used the paired or unpaired t test appropriately. 
Results 
Detection of sL-selectin Plasma by Western 
Blot Analysis 
In vitro, leukocytes and L-selectin cDNA-transfected cells 
shed L-selectin from the cell surface that can be detected in 
the culture supernatant fluid. To determine whether this pro- 
cess also occurs in vivo, the anti-LAM1-3 mAb, which 
identifies an epitope within the lectin domain, was used to 
immunoprecipitate reactive materials from normal human 
plasma. The precipitated materials were then analyzed by 
SDS-PAGE, transferred to nitrocellulose, and the presence 
of a soluble form of L-selectin was visualized by Western 
blot analysis using the anti-LAMl-14 mAh that hinds to a 
L-selectin epitope located within the SCR region. Two pre- 
dominant isoforms of sL-selectin were observed, a '~62-kD 
isoform and a 75-100-kD isoform (Fig. 1). Analysis of the 
culture supernatant fluid from PMA-stirnulated lymphocytes, 
neutrophils, and K562 cells transfected with L-selectin 
eDNA (K562-LAM) revealed ifferent, cell-specific iso- 
forms of sL-selectin (Fig. 1). Neutrophils shed a 75-100-kD 
isoform of sL-selectin that traveled as a broad band with an 
ill-defined upper border most likely due to heavy glycosyla- 
tion (33). Lymphocytes generated a 62-kD isoform and K562- 
LAM cells shed a 71-kD isoform of sL-selectin. No specific 
proteins were isolated from the supernatant fluid of untrans- 
fected K562 cells using the above assays, and preclearing the 
plasma or supernatant fluid with the anti-LAM1-3 mAb 
eliminated subsequent Western blot results (data not shown). 
Therefore, it is likely that the two predominant isoforms of 
sL-selectin identified in plasma derived from both lympho- 
cytes and neutrophils. Furthermore, sL-selectin in serum 
contained the lectin, EGF, and SCR domains as it was visu- 
alized in these xperiments u ing mAb reactive with the lec- 
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Figure 1. Different isoforms of 
sL-selectin detected by West- 
ern blot analysis. Plasma from 
a normal donor was salt frac- 
tionated, purified by affinity 
chromatography, and immu- 
noprecipitation using anti- 
LAM1-3 mAb bound to 
Sepharose beads. Lympho- 
cytes, neutrophils, and K562- 
LAM cells (1 x 107/ml) were 
incubated with PMA, and the 
culture supernatant fluids were 
isolated and concentrated ten- 
fold by ultratiltration. The 
harvested materials were ana- 
lyzed by SDS-PAGE (7.5%), 
blotted onto nitrocellulose, 
and stained with the anti- 
LAMI-14 mAb for Western 
blot analysis. 
tin (anti-LAM1-3) and SCR (anti-LAMl-14) domains, but 
the relative molecular mass of sL-selectin is smaller than that 
for L-selectin isolated from detergent solubilized cells as 
previously described (27, 40). 
Quantitation of sL-selectin in Plasma and Serum 
by ELISA 
The amount of sL-selectin found in human plasma was quan- 
titated with a sandwich ELISA using the anti-LAM1-5 mAb 
as a capture antibody and biotinylated anti-LAM1-3 mAb as 
a detecting antibody. This specific combination of mAb 
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Figure 2. Quantitation of sL-selectin levels in sera of normal indi- 
viduals. Serum was examined for sL-selectin by a sandwich ELISA 
using the anti-LAM1-5 mAb as catching antibody. Biotinylated 
anti-LAM1-3 mAb was used as detecting antibody, with avidin- 
HRP and o-phenylenediamine us d as substrate for visualization of 
anti-LAM1-3 mAb binding. Standardization of the ELISA is de- 
scribed in detail in Materials and Methods. Values represent the 
mean values + SD obtained in triplicate determinations for each 
sample. 
provided the highest level of sensitivity so that "~5 ng of sL- 
selectin could be easily detected. The level of sL-selectin de- 
termined by ELISA in the sera of a population of healthy nor- 
mal blood donors was found to be 1.6 5:0.8 #g/ml, n = 63 
(Fig. 2). In some donors, sL-selectin levels were simultane- 
ously quantitated in plasma and serum with similar results 
obtained (1.9 5:1.0 #g/ml, n = 18). It is unlikely that sL- 
selectin in plasma or serum might still be membrane bound, 
as the same levels of sL-selectin were found in serum and 
plasma before and after ultracentrifugation, sL-selectin was 
stable in whole blood left to stand at 20~ before separation 
of serum or plasma for at least 24 h. Storage of serum or 
plasma t 4~ for up to three months in the presence of azide 
or repeated thawing and freezing (up to 10 times) did not 
affect he ability to detect sL-selectin in serum. In conclusion, 
it appears that sL-selectin is stable and present at relatively 
high levels in human plasma and serum. 
Quantitation of sL-selectin in Supernatants of
Activated Leukocytes 
Stimulation or the culturing of leukocytes has been as- 
sociated with shedding of L-selectin from the cell surface. 
Therefore, experiments were carried out to determine if sL- 
selectin accumulated in culture supernatant fluid. Culture 
supernatant fluid obtained from an erythroleukemia cell line 
transfected with the pLAM-1 eDNA (K562-LAM) was found 
to contain detectable sL-selectin, in contrast to supernatant 
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Figure 3. Neutrophils and lymphocytes shed L-selectin after activa- 
tion. Culture supematant fluid from pLAM-1 cDNA-transfected 
K562 cells or untransfected cells (Control, []) were analyzed. Neu- 
trophils and lymphocytes (8 x 106/ml) were incubated in 24-well 
flat-bottom culture plates for 1 h at 37~ in the presence of medium 
alone (culture) or medium containing monocyte-colony stimulating 
factor (M-CSF), granulocyte/monocyte-colony stimulating factor 
(GM-CSF), formyl-methionyl-leucyl-phenylalanine (FLMP), TNF 
or lipopolysaccharide (LPS). Culture media were harvested, cen- 
trifuged, and supematant fluids were tested for sL-s lectin by ELISA. 
Culture medium alone served as controls (~). Values represent the 
mean OD values + SD obtained in triplicate determinations for 
each sample. These results are representative of 12 K652-LAM ex- 
periments, two neutrophil experiments, and three lymphocyte ex- 
periments. 
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fluid obtained from untransfected cells cultured at the same 
density (Fig. 3 a). Similarly, medium from freshly isolated 
neutrophils cultured at 37~ for 60 min also contained e- 
tectable sL-selectin (Fig. 3 b). Incubation of the neutrophils 
with stimuli that do not affect cell surface L-selectin expres- 
sion, granulocyte-colony stimulating factor, interleukin 1, 
monocyte-colony stimulating factor, interleukin 6, interferon 
% and interleuldn 4, did not induce an increase in sL-selectin 
in these experiments. However, stimulation with formylated 
methionine-leucine-phenylalanine, lipopolysaccharide, gran- 
ulocyte/monocyte-colony stimulating factor, interleukin 8, 
and tumor necrosis factor (TNF) induced L-selectin shed- 
ding corresponding to their potency to stimulate cell surface 
shedding (Fig. 3 b and data not shown). Culturing lympho- 
cytes for 60 rain at 37~ caused some shedding of L-selectin, 
which was greatly enhanced by PMA treatment (Fig. 3 c). 
In similar experiments, quantitation of the amount of sL- 
selectin found in the supernatant fluid after activation of neu- 
trophils and lymphocytes (1 x l07 cells/ml) varied between 
~10-30 ng/ml. However, PMA-activation i  PBS oflympho- 
cytes for >25 min, and neutrophils for >10 min, resulted in 
the gradual degradation of sL-selectin. Degradation was not 
observed in the supernatant from K562-LAM cells, where 
sL-selectin was consistently found at concentrations of 22 5= 
6 ng/ml (1.7 5: 0.5% of standard plasma; n = 14). In experi- 
ments not shown, elevated levels of sL-selectin were also 
detected in the culture supernatant fluid of lymphocytes 
cultured with phytohemagglutinin, concanavalin A, and 
pokeweed mitogen for 3-6 d at 37~ These mitogens are 
known to cause cell surface loss of L-selectin (51). Thus, loss 
of L-selectin from the cell surface directly correlates with an 
increase of sL-selectin in the culture medium. 
Inhibition of Lymphocyte Binding to Activated 
Endothelium by sL-selectin 
sL-selectin was semipurified from plasma by salt fraction- 
ation followed by affinity chromatography with the anti- 
LAM1-3 mAb. The column eluate was concentrated, and the 
level of sL-selectin present was quantitated by ELISA and 
adjusted to ~15 t~g/ml (6-10% of total eluate protein), sL- 
selectin, at different concentrations, in RPMI 1640/10% 
FCS was incubated (15 rain, 4~ with cytokine-activated 
endothelial cells before xamining lymphocyte attachment to 
endothelium through L-selectin. While sL-selectin at physi- 
ological concentrations caused only partial inhibition of 
lymphocyte attachment (32.1 + 15.9%, n = 10), it was 
found to inhibit most L-selectin-dependent lymphocyte 
binding at concentrations of 8/~g/ml (52-100 %) and caused 
almost total inhibition of L-selectin-mediated binding at 
12-15 #g/ml (93-100%; Fig. 4 depicts a typical dose re- 
sponse curve). Lymphocyte binding mediated by L-selectin 
was calculated as the difference between total binding at any 
given concentration f sL-selectin and lymphocyte binding 
found in the presence of anti-LAM1-3 mAb, which blocks 
all L-selectin mediated adhesion (43). Importantly, sL- 
selectin at 15 pg/ml caused no additional inhibition of lym- 
phocyte binding beyond that obtained with anti-LAM1-3 
mAb alone. When the sL-selectin samples were precleared 
with the anti-LAMl-15 mAb (which does not block L-selec- 
tin adhesion) before the assays, the preparation was not able 
to inhibit lymphocyte attachment, demonstrating that sL- 
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Figure 4. Inhibition of lymphocyte binding to activated endothe- 
lium by sL-selectin. Confluent monolayers of endothelial cells 
grown on slides were activated with TNF (100 U/ml) for 3 h, fol- 
lowed by incubation (4~ 15 min) with medium containing various 
concentrations of sL-selectin (in 75 #1) that was semipurified from 
plasma nd resuspended in RPMI 1640/10% FCS. Blood lympho- 
cytes (5 x 106) in 75/~1 of medium (,) or medium containing 
anti-LAM1-3 mAb (15 pg, o) were layered onto the slides for 20 
min at 4~ with rotation at 64 rpm. Attachment oflymphocytes in 
the presence of anti-LAM1-3 mAb indicates L-selectin-indepen- 
dent binding. Results obtained with a portion of the sL-selectin 
preparation (equivalent tothat used at 15.7/~g/ml) that was first pre- 
cleared with the anti-LAMl-15 mAb are shown as open symbols. 
Values represent the means + SD of six counted fields, and are typ- 
ical for three experiments. 
selectin mediated the inhibition (Fig. 4). Thus, it appears 
that sL-selectin is capable of inhibiting L-selectin-specific 
lymphocyte adhesion to endothelium by binding to its puta- 
tive endothelial ligand. 
The inhibitory capacity of sL-selectin at normal physio- 
logical concentrations (1.5 #g/ml) was further evaluated to 
determine if it could alter the interaction of lymphocytes with 
endothelium. Endothelium was activated with TNF (100 
U/ml) for different periods of time to induce the L-selectin 
ligand in a manner similar to what might happen during 
the initiation of an inflammatory esponse. During the course 
of induction of the L-selectin ligand, sL-selectin treatment 
of the endothelium caused aconsistent, but small, inhibition 
of L-selectin-dependent lymphocyte attachment (30% at 2 h, 
43 % at 3 h, 41% at 4 h, 15 % at 5 h, and 2 % at 6 h) (Fig. 5). 
Again, the combination of sL-selectin with the anti-LAM1-3 
mAb did not cause a greater inhibition than that observed 
with the mAb alone. Thus, during the development of an in- 
flammatory response, it is likely that sL-selectin will be able 
to alter the course of leukocyte attachment, although the in- 
fluence appears to be small in this in vitro assay. 
sL-selectin in Serum Blocks Anti-L-selectin 
mAb Binding 
The presence of circulating sL-selectin was further verified 
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Figure 5. Inhibition of lymphocyte-endothelial b nding by physio- 
logical evels of sL-selectin. Confluent monolayers of endothelial 
cells grown on slides were activated with TNF (100 U/ml) for vari- 
ous time periods as indicated. The slides were then washed and in- 
cubated (4~ 15 rain) with 75 td of medium alone (circles) or me- 
dium containing 1.5/~g/ml sL-selectin that was semipurified from 
plasma (squares). Blood lymphocytes (5 x 106) in 75/zl of me- 
dium (I, e) or medium containing the anti-LAM1-3 mAb ([], o; 
15/~g) were layered onto the slides for 20 min at 4~ with rotation 
at 64 rpm. Attachment of lymphocytes in the presence of anti- 
LAM1-3 mAb indicates L-selectin-independent binding. Values 
represent the means 5- SD of six counted fields, and are typical for 
three xperiments. Time points designated by asterisks indicate sta- 
tistically significant differences (P < 0.005) between attachment 
with or without sL-selectin present. 
by demonstrating that the reactivity of anti-L-selectin mAb 
with L-selectin § ceils could be inhibited by plasma. When 
lymphocytes were stained using anti-L-selectin mAb in un- 
diluted human plasma, no significant staining was obtained 
at concentrations of mAb that were saturating in RPMI/FCS 
(data not shown). Next, lymphocytes (1 • 106/100 #1) were 
incubated with various concentrations of L-selectin-directed 
mAb diluted (1:100) in autologous plasma or autologous 
plasma which had been precleared of sL-selectin by immu- 
noprecipitation. After completion of indirect immunofluo- 
rescence staining, antibody binding was assessed by flow 
cytometry. In most cases, the presence of plasma inhibited 
anti-L-selectin mAb staining when the mAbs were used at 
2 to 5 #g/ml (Fig. 6). Thus, ,x,13-33 pM IgG~ (150 kD) 
bound to "~21 pM sL-selectin (75 kD) based on the concen- 
tration of sL-selectin present in plasma (1.6/zg/ml) deter- 
mined as outlined above, sL-selectin-dependent inhibition of 
mAb binding was seen in plasma for mAb which recognize 
the lectin domain (anti-LAM1-3, -4, and -10) and the EGF- 
like domain (anti-LAM1-5, and -15). In contrast, binding of 
the anti-LAMl-1 mAb, which binds an epitope in the EGF- 
like domain, was not significantly inhibited by the presence 
of plasma (Fig. 6 D). 
The LAMI-1 Epitope was not Detected on sL-selectin 
from Human Plasma 
Since anti-LAMl-1 mAb binding to lymphocytes was not in- 
hibited by plasma, the epitope identified by this mAb may 
not be present on sL-selectin. To examine this further, 
ELISA were performed in which different L-selectin-di- 
rected mAbs were bound to an ELISA plate as capture anti- 
bodies with the anti-LAM1-3 mAb as the detecting antibody. 
Lectin domain-specific antibodies (anti-LAM1-6, -7, -10, and 
-11) and EGF-like domain specific mAb (anti-LAM1-5 and 
-15) gave strong, easily detectable positive signals (Fig. 7). 
Wells coated with the anti-LAM1-3 and -4 mAb, which 
cross-block the binding of the detecting antibody (anti- 
LAM1-3), served as internal controls for background re- 
activity. In contrast o all other mAb, anti-LAMl-1 gave a 
signal that was not significantly different from background, 
as defined by using BSA as the capture reagent. Thus, the 
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Figure 6. The influence of sL- 
selectin on the binding of anti- 
L-selectin mAb to lympho- 
cytes. Heparinized plasma 
was either precleared of sL- 
selectin using anti-LAM-Seph- 
arose or left on ice. Lympho- 
cytes from the same donor 
were resuspended in 100 #l of 
plasma (e) or predicated plas- 
ma (o). Various anti-L-selec- 
tin mAbs at different concen- 
trations were added to the 
plasma (1:100) and mAb bind- 
ing was assessed by indirect 
immunofluorescence staining. 
X~vhshed lymphoeytes were fixed 
in paraformaldehyde, and the 
intensity of fluorescence stain- 
ing was determined by flow 
cytometry. Values represent 
the relative mean intensity of 
fluorescence for stained ceils. 
These results are representa- 
tive of those obtained in two 
sets of experiments. 
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Figure 7. The epitope identified by the anti-LAMl-1 mAb is not de- 
tected on sL-selectin from plasma. Plasma was tested for detectable 
sL-selectin by a sandwich ELISA using the indicated anti-L-selec- 
tin mAb as catching antibody, and biotinylated anti-LAM1-3 mAb 
as detecting antibody. Anti-LAM1-3 mAb binding was visualized 
using avidin-HRP and o-phenylenediamine as substrate. BSA 
bound to the wells of the ELISA plate served as a control. Antibod- 
ies anti-LAM1-3 and -4 cross-block the binding of the detecting an- 
tibody (anti-LAMI-3). Values represent mean 5: SD of OD values 
obtained in triplicate wells. These results are representative of three 
similar experiments. 
epitope located within the EGF-like region which is spe- 
cifically recognized by the anti-LAMl-1 mAb appears to be 
lost from L-selectin upon shedding. As L-selectin was easily 
recognized by all L-selectin-specific mAb in immunofluo- 
rescence staining of lymphocytes and all three extracellular 
domains are preserved on sL-selectin found in plasma, con- 
formational changes in the L-selectin protein may lead to the 
loss of the EGF-like domain related LAMI-1 epitope. 
To determine whether the transmembrane or cytoplasmic 
regions of L-selectin are necessary to uphold the complete 
tertiary structure of its extraceUular domains, a second form 
of soluble L-selectin, a LAM-IgG fusion protein was gener- 
ated and epitope-mapped by ELISA. The chimeric eDNA 
used to generate the fusion protein was constructed so that 
it contained essentially the entire extracellular region of 
L-selectin. Culture supernatant fluid of COS cells that were 
transiently transfected with the chimeric eDNA were tested 
for the production of LAM-IgG by ELISA. The anti-LAM1- 
5, -7, and -15 mAb, which detected sL-selectin in plasma nd 
in supernatant fluid from PMA-stimulated K562-LAM cells, 
also bound the LAM-IgG chimera t similar levels (Fig. 8). 
In contrast, while the anti-LAMl-1 mAb failed to generate 
a significant signal with sL-selectin from plasma nd K562- 
LAM transfectants, it readily bound the LAM-IgG fusion 
protein (Fig. 8). Thus, it is likely that sL-selectin generated 
in vivo or in vitro loses a conformational determinant that 
is required for anti-LAMl-1 mAb binding. 
Discussion 
The presence of different isoforms of intact sL-selectin in 
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Figure 8. Detection of the LAMI-1 epitope, which is lost on sL- 
selectin from plasma, on a soluble LAM-IgG fusion protein. A 
LAM-IgG chimeric eDNA was constructed and the fusion protein 
was expressed inCOS cells. After 3 d of culture, supernatant fluids 
were harvested and examined for LAM-IgG (-) content by 
ELISA. In parallel, supernatant fluid of PMA-stimulated K562- 
LAM cells ([]) and plasma (diluted 1/5) ([]) were examined. The 
indicated mAbs were bound to the wells of an ELISA plate and the 
ELISA was carried out as described in Fig. 7. Bars denote mean 
OD values + SD of triplicate determinations. These results are rep- 
resentative of those obtained in three separate xperiments. 
plasma and serum was revealed by Western blot analysis 
(Fig. 1). sL-selectin in serum appeared to be derived from 
both lymphocytes and neutrophils ince the analysis of sL- 
selectin isolated from neutrophils (95-105 kD) and lym- 
phocytes (74 kd) produced bands of corresponding relative 
molecular mass. The differences in relative molecular mass 
between lymphocyte and neutrophil sL-selectin most likely 
result from differences in glycosylation of a single protein 
species since only a single L-selectin mRNA species has 
been identified (33), and K562 cells transfected with the 
pLAM-1 eDNA that is complementary to this mRNA also 
produced a different isoform of sL-selectin. Cleavage of 
L-selectin is likely to be proximal to the membrane spanning 
region encoded by exon VHI; cleavage in this region would 
account for the small difference in relative molecular mass 
between the intact cellular L-selectin molecule and its shed 
form (23, 28, 40). This is supported by the extraordinarily 
high degree of conservation of exon VIII between human 
L-selectin and the corresponding region of mouse L-selectin 
(9, 33). In addition, anti-L-selectin mAb binding studies 
demonstrated that the lectin, EGF-like, and SCR domains 
are retained by sL-selectin (Figs. 1 and 7). It is therefore pos- 
sible that the factor in rat lymph characterized by Chin and 
Woodruff as being capable of inhibiting lymphocyte attach- 
ment to HEV was in part sL-selectin (4-6). 
While the direct demonstration of sL-selectin in plasma 
and supernatant fluid from activated neutrophils and lympho- 
cytes confirms that the in vivo and in vitro loss of L-selectin 
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surface xpression is due to shedding, development of the 
sL-selectin-ELISA allowed for the first time an easy, effi- 
cient, and sensitive method for quantification of sL-selectin. 
Remarkably, in a population of normal healthy blood donors 
the mean serum level of sL-selectin was determined tobe 1.6 
• 0.8/~g/ml. The concentration of sL-selectin was deter- 
mined by comparison with a reference plasma sample that 
had been standardized by two independent means, and 
ranged between 0.85 and 1.9 #g/ml. The mean of this range 
of values of 1.3/~g/ml was therefore chosen as the basis of 
all calculations. Experimental data derived from shedding 
experiments inK562-LAM transfectants further substantiate 
the validity of this estimate (44a). K562-LAM cells express 
30,000-43,000 L-selectin molecules on each cell as deter- 
mined by Scatchard analysis. After PMA stimulation of 
these cells, all L-selectin molecules (71 kD) are shed. 
Thereby, the concentration f sL-selectin in plasma can be 
calculated by comparing the concentration f sL-selectin in 
medium (13% the concentration of standard plasma) shed 
from K562 transfectants (1 x 107 cells/ml) to a titration 
curve of standard plasma. According to this calculation, 
plasma concentrations would lie in the range of 2.1-3.0 
#g/ml. Similar considerations make it highly unlikely that the 
amount of sL-selectin found in serum or plasma is generated 
from the shedding of cell surface L-selectin by blood leuko- 
cytes present during the preparation of the samples: the 
quantity of sL-selectin actually found in serum is 10-25-fold 
higher than the quantity of L-selectin that could maximally 
be shed from the cell surface of leukocytes (~4 x 10~/ml) 
present in the samples, since most leukocytes express 
50,000-100,000 receptors/cell as determined by Scatchard 
analysis (44a). Therefore, sL-selectin must be generated by 
the ongoing shedding of cell surface L-selectin from leuko- 
cytes in vivo. 
Another adhesion molecule, ICAM-1, was recently shown 
to circulate in plasma t a concentration of 0.16 #g/ml (35), 
a concentration 10-fold lower than that found for sL-selectin. 
Functional activity of soluble ICAM-1, however, could only 
be demonstrated when it was immobilized to plastic (35). 
In contrast, sL-selectin semipurified from plasma inhibited 
L-selectin-mediated lymphocyte attachment a suboptimal 
levels of ligand expression on TNF-activated endothelium in
a dose-dependent manner with complete inhibition at ,x,8-15 
#g/ml (Fig. 4). At concentrations of sL-selectin similar to 
those found in the plasma of normal blood donors, a small 
but significant (p < 0.005) inhibition of leukocyte endothelial 
binding was observed at various levels of ligand expression 
(Fig. 5). Similarly, using a soluble fusion protein composed 
of the Fe portion of human IgG and the extracellular domains 
of MEL-14 at 1 t~g per tissue section, Vvhtson et al. (53) have 
found •75 % inhibition of lymphocyte binding to HEV. Pre- 
liminary studies uggest that circulating sL-selectin may be 
functional in vivo since immunohistochemical staining of 
tissues with anti-L-selectin mAb revealed sL-selectin 
specifically bound to the luminal surface of endothelial cells, 
both on HEV endothelium and at sites of inflammation 
(Munro, M., B. Schleiffenbaum, and T. E Tedder, manu- 
script in preparation). This is not unexpected, asthe MEL- 
14-IgG fusion protein also binds to HEV in vitro (53). 
High levels of relatively low avidity sL-selectin circulating 
in plasma might serve as a biological adhesion buffer system 
to prevent he attachment of leukocytes at sites where low 
level upregulation of the L-selectin ligand has occurred on 
endothelial cells, similar to the function proposed for soluble 
P-selectin (12). This hypothesis  in keeping with the small 
but consistent inhibitory effect of physiological concentra- 
tions of sL-selectin on L-selectin specific lymphocyte attach- 
ment o HUVEC during the course of ligand induction (Fig. 
5). The inhibitory effect of sL-selectin may be biologically 
most relevant at low levels of ligand expression. Future 
studies on the binding affinity of sL-selectin for its en- 
dothelial igand will have to be carried out to determine 
whether sL-selectin can efficiently compete with cell-bound 
receptor for ligand. Since the number of sL-selectin mole- 
cules in blood is much higher than the number of cell-surface 
receptors in the same volume of blood, it is likely that sL- 
selectin is of a lower affinity. Alternatively, their affinities 
may be equivalent, but cell-surface receptors may function 
in a cooperative manner or the localized relative density of 
receptors on the ceil surface may be higher than the corre- 
sponding relative density in solution. It is also possible that 
the increase in affinity of L-selectin which follows cellular 
activation may allow the competitive displacement of sL- 
selectin from the endothelial surface (41). 
An interesting finding was that sL-selectin did not contain 
the epitope wihhin the EGF-like domain identified by the 
anti-LAMl-1 mAb, while this epitope was readily demon- 
strated on the LAM-IgG fusion protein (Fig. 8) and is found 
on cell-surface L-selectin (21, 42, 51). This was revealed 
both by ELISA (Fig. 7) and by a lack of competitive inhibi- 
tion in immunofluorescence staining of leukocytes (Fig. 6). 
Since the EGF-like domain is retained in sL-selectin, altera- 
t_ions in the tertiary structure of L-selectin may have occurred 
after shedding that result in a lack of anti-LAMl-1 mAb 
binding. It is possible that the Fc portion of IgG fused to the 
L-selectin extracellular domain was sufficient to stabilize the 
tertiary structure of L-selectin, so that anti-LAMlq mAb is 
still able to recognize its epitope on this soluble form of the 
molecule. Anti-LAMI-1 mAb binding to L-selectin ot only 
inhibits leukocyte attachment to endothelium, but also in- 
duces an increase in the binding of PPME and fucoidin (21, 
42), carbohydrates which define L-selectin lectin activity 
(16, 21, 43, 47, 56, 57). Since conformationai changes involv- 
ing the LAMlq epitope may be important for the increase 
in L-selectin affinity that follows leukocyte activation (41), 
it is conceivable that the loss of the LAMI-1 epitope results 
in a lower affinity of sL-selectin for ligand. 
The levels of sL-selectin ormally found in human serum 
competitively inhibited the in vitro binding of L-selectin- 
directed mAbs to leukocytes. This finding has important im- 
plications for future in vivo studies both in animals and hu- 
mans. Functionally active mAbs will have to be introduced 
into animals in large enough quantities to saturate binding 
to sL-selectin in blood to allow efficient binding of mAb to 
leukocytes and subsequent modulation of leukocyte func- 
tion. In addition, the formation of immune complexes be- 
tween sL-selectin and L-selectin directed mAb will have to 
be considered. The use of F(ab): or F(ab) fragments in- 
stead of whole immunoglobulin might also be preferable, s- 
pecially when neutrophil functions are to be evaluated. 
Therefore, inhibitory mAb such as anti-LAMl-1 which 
recognizes epitopes on L-selectin that are lost on sL-selectin 
might also prove helpful. 
It has been proposed that L-selectin shedding is necessary 
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for the transmigration of leukocytes through endothelium al- 
lowing rapid deadhesion of the leukocytes from endothelial 
cell surfaces. However, immunohistochemical staining of 
lymph nodes and inflamed tissues demonstrated variable 
proportions of L-selectin + extravascular lymphocytes, neu- 
trophils, and monocytes (Munro, M., B. Schleiffenbaum, 
and T. E Tedder, manuscript in preparation). Therefore, it 
is possible that once leukocytes localize in tissues, they con- 
tinue to express L-selectin, but this receptor is continually 
shed. As only a small proportion of the body's leukocytes are 
normally found in the circulation, it might be hypothesized 
that tissue localized leukocytes represent a major source of 
sL-selectin. The in situ production of sL-selectin by tissue- 
localized leukocytes would help explain the unpredicted high 
level of sL-selectin found in the circulation. However, the 
L-selectin ligand expressed by HEV of peripheral lymph 
nodes is shed in vitro and may also be shed in vivo (28). 
Thereby, if the ligand is shed at high enough levels in vivo, 
it might adhere to sL-selectin, thus inhibiting its ability to 
affect cell adhesion in vivo. In addition, significant levels of 
the shed ligand may also serve as an inhibitor of L-selectin- 
mediated adhesion to endothelium. Nonetheless, the pres- 
ence of a soluble isoform of L-selectin with functional activ- 
ity in serum indicates a new potential mechanism for in vivo 
regulation of leukocyte attachment o endothelium. 
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